[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-364605-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-364605-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","urinary-extracellular-vesicle-n-glycomics-identifies-diagnostic-glycosignatures-for-bladder-cancer","Urinary extracellular vesicle N-glycomics identifies diagnostic glycosignatures for bladder cancer","","Urinary extracellular vesicle (EV) N-glycomics is explored as a non-invasive diagnostic approach for bladder cancer, leveraging direct contact between urine and the bladder. High-throughput analysis profiles urinary EV N-glycans, identifying 252 N-glycans across 333 individuals. Bladder cancer cases show decreased fucosylation and increased sialylation. An eight–N-glycan diagnostic model achieves ROC AUC of 0.88 and 0.86 in validation cohorts and separates NMIBC and MIBC from healthy controls. Comparative EV–cell glycoproteomics links cancer-associated glycan signatures to immune activities.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/urinary-extracellular-vesicle-n-glycomics-identifies-diagnostic-glycosignatures-for-bladder-cancer/364605/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/urinary-extracellular-vesicle-n-glycomics-identifies-diagnostic-glycosignatures-for-bladder-cancer/364605.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why focus on urinary extracellular vesicles for bladder cancer diagnostics?","Question",{"text":63,"@type":64},"Urinary EVs come from nearly all cell types and are released into urine, enabling biomarker discovery through direct urine–bladder contact. Their non-invasive source and repeated sampling make them suitable for screening and monitoring.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What glycosylation changes were observed in bladder cancer urinary EVs?",{"text":68,"@type":64},"Urinary EVs from bladder cancer patients show decreased fucosylation and increased sialylation compared with controls.",{"name":70,"@type":61,"acceptedAnswer":71},"How well does the eight–N-glycan model perform in validation?",{"text":72,"@type":64},"The eight–N-glycan diagnostic model achieves strong performance in both validation cohorts, with ROC AUC values of 0.88 and 0.86, and it distinguishes both NMIBC and MIBC from healthy individuals.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},364605,1790229321,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article [https://doi.org/10.1038/s41467-025-57633-9](https://doi.org/10.1038/s41467-025-57633-9)  \nUrinary extracellular vesicle N-glycomicsidentiﬁes diagnostic glycosignatures for bladder cancer  \nReceived: 27 May 2024  \n\n| Accepted: 27 February 2025 |\n| --- |\n| |\n| Check for updates |\n\nYang Li1,4, Bin Fu 1,4, Maoyu Wang2, Weiyu Chen1, Jiawei Fan1, Yueyue Li1,  \nXuejiao Liu1, Jun Wang1, Zhensheng Zhang2 , Haojie Lu1,3  & Ying Zhang 1,3   \nBladder cancer (BC) is the most common urologic malignancy, facing enormous diagnostic challenges. Urinary extracellular vesicles (EVs) are promising source for developing diagnostic markers for bladder cancer because of the direct contact between urine and bladder. This study pioneers urinary EV N-glycomics for bladder cancer diagnosis. We have generated a comprehensive N-glycome landscape of urinary EVs through high-throughput N-glycome analysis, identifying a total of 252 N-glycans from 333 individuals. In bladder cancer patients, urinary EVs exhibit decreased fucosylation and increased sialylation level. An Eight N-glycan diagnostic model demonstrates strong performance in both validation cohorts, achieving ROC AUC values of 0.88 and 0.86, respectively. Furthermore, this model successfully differentiates both non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) from healthy individuals, underscoring the model’s superiority. Moreover, urinary EVs N-glycoproteomic analysis reveals that the glycoproteins carrying cancer-associated N-glycan signatures are closely associated with immune activities. The N-glycome comparative analysis of EVsand their source cells indicate that the glycosylation proﬁles of EVs do not completely match the glycosylation backgrounds oftheir source cells. In summary, our study establishes urinary EV N-glycomics as a non-invasive BC screening tool and provide a framework for EV glycan biomarker discovery across cancers.  \nBladder Cancer (BC) represents the most common malignant tumors within the urinary system1. In 2022, worldwide incidence of BC was reported at approximately 614,000 new cases, with 220,000 deaths2. According to the depth of invasion into the bladder wall, BC can beclassiﬁed into two principal categories including non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). NMIBC represents about 75% of cases and notorious for its high recurrence risk, with 50% to 70% of patients experiencing recurrence within ﬁve years and potential progression toMIBC, which necessitates  \nfrequent monitoring3. MIBC accounts for the remaining 25%, characterized by a higher metastasis risk and a signiﬁcantly lower ﬁve-year survival rate, often below 10%, requiring regular assessment to update patient conditions4.  \nClinically, cystoscopy, urine cytology, and imaging techniques constitute the common modalities for diagnosing BC. Cystoscopy, regarded as the gold standard for diagnosing BC, is an inherently invasive procedure that often results in signiﬁcant discomfort.5 However, cystoscopy is inevasibly invasive and causes unbearable  \n1Department of Chemistry, Minhang hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai, PR China. 2Department of Urology, First Afﬁliated Hospital, Naval Medical University, Shanghai, China. 3NHC Key Laboratory of Glycoconjugates Research, Fudan University, Shanghai, PR China.  \n4These authors contributed equally: Yang Li, Bin Fu. e-mail: [13761178177@163.com](13761178177@163.com); [luhaojie@fudan.edu.cn](luhaojie@fudan.edu.cn); [ying@fudan.edu.cn](ying@fudan.edu.cn)  \ndiscomfort. Urine cytology, while non-invasive, shows low sensitivity, especially for low-grade cancers6,7. Imaging techniques like ultrasonography, computed tomography (CT), computed tomography urography (CTU) and others help in determining the extent of lesions but shares the low sensitivity issue8. During the past decades, several urine-derived markers, including nuclear matrix protein 22 (NM","cbCaisBbFfp5YAKC","https://ap.wps.com/l/cbCaisBbFfp5YAKC","pdf",3413915,17,"English","# Background and clinical needs\n## Diagnostic challenges of bladder cancer\n# Urinary EV N-glycomics strategy\n## Rationale for using urinary extracellular vesicles\n# Glycan profiling results\n## N-glycan landscape and differential features\n# Diagnostic model performance\n## ROC validation and NMIBC/MIBC discrimination\n# Mechanistic insight from EV glycoproteomics\n## Association with immune activities\n# Comparative analysis and implications\n## EV vs source cell glycosylation mismatch\n## Framework for glycan biomarker discovery","[{\"question\":\"Why focus on urinary extracellular vesicles for bladder cancer diagnostics?\",\"answer\":\"Urinary EVs come from nearly all cell types and are released into urine, enabling biomarker discovery through direct urine–bladder contact. Their non-invasive source and repeated sampling make them suitable for screening and monitoring.\"},{\"question\":\"What glycosylation changes were observed in bladder cancer urinary EVs?\",\"answer\":\"Urinary EVs from bladder cancer patients show decreased fucosylation and increased sialylation compared with controls.\"},{\"question\":\"How well does the eight–N-glycan model perform in validation?\",\"answer\":\"The eight–N-glycan diagnostic model achieves strong performance in both validation cohorts, with ROC AUC values of 0.88 and 0.86, and it distinguishes both NMIBC and MIBC from healthy individuals.\"}]","Urinary extracellular vesicle N-glycomics identifies diagnostic glycosignatures for bladder cancer | PDF",1790158529,43,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac0634fd499c1818fa3f7352d53d68cb.webp",983,1305,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8410834e3974ae36d8e59c7f0b564298.webp",982,1304,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3604991b079be2cfd01105ba5a12d105.webp",981,1303,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b3be70cf132a6fef66b9667bf179ef37.webp",980,1301]